lntervirolog
clantitrypsin
plasma
protein
protect
elast
tissu
proteolyt
sturman
l
holm
k
v
attack
consequ
genet
defici
oxid
reactiv
centr
adv
viru
re
cigarett
smoker
result
degen
lung
diseas
emphysema
structur
sidden
wege
h
ter
meulen
v
studi
explain
mechan
involv
also
drawn
attent
new
curr
top
microbiol
immunol
famili
serin
proteinas
inhibitor
specif
inhibitor
rottier
p
j
van
der
zeijst
b
primarili
depend
singl
amino
acid
reactiv
centr
sitedirect
spaan
w
j
horzinek
c
ed
mutagenesi
enabl
product
specif
design
inhibitor
adv
exp
med
biol
therapeut
use
includ
improv
replac
ctantitrypsin
defici
ture
presum
design
firmli
fix
aantichymotrypsin
realli
atantitrypsin
rel
small
reactiv
centr
expos
site
leuserpin
inhibitor
proteinas
glycoprotein
mr
optim
substrat
configurcleav
leucin
terminolog
amino
acid
residu
three
oligo
presumpt
allow
concis
descript
saccharid
side
chain
readili
difth
cleav
structur
reactiv
centr
inhibitor
avoid
mislead
comfus
tissu
space
sprung
like
mousetrap
mitment
target
enzym
one
emform
complex
target
promethionin
one
end
barrass
exampl
misnam
ateas
princip
neutrophil
elastas
molecul
separ
antitrypsin
primarili
complex
inhibitor
enzym
serin
intact
inhibitor
trypsin
similarli
asubsequ
remov
circuinhibitor
sequenc
preced
antichymotrypsin
primarili
lation
catabol
liver
methionin
must
pluck
inhibitor
chymotrypsin
rather
spleen
give
strain
loop
cathepsin
g
chymas
inhibitor
thought
trap
join
serin
fig
thu
ambigu
histor
nomenclaproteas
present
reactiv
site
cleav
inhibitor
stabl
ture
clearli
illustr
recent
ideal
substrat
rapid
uncleav
inhibitor
metast
recognit
l
homologu
associ
enzym
explain
difficulti
crystal
mous
human
cqantichymotrypsin
inhibitor
neglig
dissoci
nativ
atantitrypsin
mous
anantichymotrypsin
consequ
format
tightli
view
molecul
lysin
rather
leucin
reactiv
bound
enzymeinhibitor
complex
expos
strain
reactiv
centr
fit
centr
make
lyserpin
rather
reactiv
site
alantitrypsin
well
observ
leuserpin
henc
inhibit
situat
near
cterminu
centr
vulner
reactiv
site
cleavchymotrypsin
highli
effect
methionin
residu
posit
age
nonserin
proteinas
inhibitor
trypsinlik
proteas
complex
format
elastas
suscept
reactiv
centr
abil
recogn
reactiv
accompani
proteolyt
attack
methionin
oxid
centr
homolog
also
allow
bond
methionin
identif
put
inhibitori
adjac
serin
posit
serpin
snperfamili
activ
two
unexpect
member
key
role
methionin
defin
clear
whole
serpin
famili
ovalbumin
specif
inhibit
indic
famili
serin
proteinas
inhibitor
angiotensinogen
neither
tabl
serpin
gener
diverg
ancestr
known
inhibitori
reactiv
centr
p
residu
act
inhibitor
period
function
howev
retain
homa
bait
appropri
serin
proteinmillion
year
best
document
olog
reactiv
site
perhap
ase
affin
familiar
homolog
arantiovalbumin
alaserpin
angioprotein
chemist
ie
methionin
trypsin
antithrombin
tensinogen
glyserpin
valin
elastas
lysin
trypsin
antichymotrypsin
increasangiotensinogen
particularli
inleucin
chymotrypsin
arginin
ing
evid
famili
terest
addit
famili
thrombin
includ
inhibitor
recogn
physiolog
role
descript
concept
inhibicontrol
major
proteolyt
cascad
sourc
small
peptid
control
tor
trap
activ
centr
bodi
coagul
blood
pressur
angiotensin
ii
act
bait
support
crystallograph
structur
alantitryp
tabl
cleav
tenresidu
met
one
ten
zz
homozygot
segment
nterminu
liver
diseas
usual
earli
infanc
molecul
activ
whether
result
directli
gen
highlight
likelihood
accumul
z
protein
serpin
gener
ntermin
z
liver
consequ
plasma
tail
molecul
form
second
defici
inhibitor
still
function
site
tail
variabl
debat
clear
howev
length
individu
member
set
asa
lung
diseas
directli
relat
famili
order
struc
plasma
defici
ture
exterior
molecul
access
cleavmet
smoke
emphysema
age
ntermin
tail
cours
lifetim
like
candid
major
heparin
b
gradual
irrevers
loss
elast
bind
site
antithrombin
oqanti
fig
reactiv
centr
elrantitrypsin
lung
age
thirti
trypsin
ntermin
cleavag
signifiexpos
strain
loop
probabl
hing
resilung
elast
volum
litr
cant
caus
microheterogen
due
site
z
mutat
peopl
limit
inhibitor
whether
releas
lung
function
sinc
conpeptid
function
physiolog
experiment
result
fit
well
sider
individu
variat
messeng
histolog
chang
rna
lost
suffici
mutat
defici
diseas
messag
mrna
z
proport
elast
volum
two
genet
variat
amino
protein
readili
extract
give
crippl
lung
diseas
emphyacid
sequenc
oqantitrypsin
human
liver
shown
present
sema
chanc
get
emphyequival
amount
addit
sema
greatli
increas
particular
import
conmrna
cellfre
system
show
acceler
loss
capac
number
fine
european
result
decreas
plasma
concentr
equal
translat
addit
oligoof
factor
like
involv
saccharid
side
chain
z
two
document
occurr
accelerinhibitor
z
defici
variant
differ
confirm
inject
ate
loss
heavi
smoker
normal
qantitrypsin
substimrna
xenopu
oocyt
howpeopl
sever
cqantitrypsin
detut
two
differ
glutam
acid
ever
although
thereisequalproduct
ficienc
group
mean
process
decreas
annual
loss
ml
per
year
product
defici
gene
secret
z
antitrypsin
consider
individu
vari
glu
val
present
whatev
mechan
involv
ation
onset
emphysema
concentr
normal
gene
z
gene
end
result
signific
unlik
event
normal
defici
plasma
atantitrypsin
individu
becom
like
event
glu
ly
two
glutam
european
heteroheavi
smoker
also
individu
acid
substitut
variant
form
import
salt
bridg
zygot
z
defect
ie
genotyp
homozyg
alantitrypsin
denorm
stabil
molecul
mz
nearli
one
thousand
ficienc
howev
becom
certain
sever
zz
sz
defici
event
crantitrypsin
defici
surpris
variant
homozyg
zz
individu
individu
also
smoke
decreas
stabil
measur
heat
liabl
develop
liver
lung
diseas
loss
expiratori
volum
increas
stress
loss
stabil
variant
compat
increas
turnov
nascent
polypeptid
prime
caus
decreas
iiii
product
like
presenc
aberr
intron
splice
site
introduc
point
mutat
sever
z
defici
r
great
interest
involv
defect
pathway
process
secret
polypeptid
electron
microscopi
show
gross
accumul
z
cq
antitrypsin
level
roughto
smooth
endoplasm
junction
fig
iij
thu
partial
blockag
incomplet
process
arantitrypsin
enter
golgi
vesicl
process
suggest
blockag
transport
rather
failur
oligo
fig
electron
micrograph
liver
zz
patient
z
antitrypsin
accumul
larg
saccharid
process
amorph
granul
endoplasm
reticulurn
ml
per
year
group
emphysema
age
forti
dead
fiftyf
acceler
onset
emphysema
readili
explain
nativ
term
current
belief
elast
lung
maintain
balanc
releas
destruct
enzym
princip
elastas
protect
effect
inhibitor
princip
antitrypsin
balanc
oxidis
proteas
antiproteas
destroy
genet
defici
ppe
plasma
prt
met
val
ctlantitrypsin
genet
defici
oiat
yeast
yeast
combin
habitu
smoke
doubl
jeopardi
sinc
smoke
result
fig
gelatin
plate
incorpor
inhibitor
give
endpoint
measur
porcin
pancreat
increas
concentr
leucoelastas
activ
oxid
chloramin
control
activio
without
inhibitor
cyte
lung
consequ
shown
addit
plasma
yeast
addit
smoker
subject
anoth
risk
factor
oxid
stress
z
bacteria
discharg
oxygen
freemut
result
analysi
conthat
inactiv
antitrypsin
investirad
isol
focu
firm
satisfi
way
gation
oxid
inactiv
releas
proteas
give
tissu
liquea
predict
mutat
reveal
subtl
control
mechan
faction
liquefact
occur
reactiv
centr
methionin
built
reactiv
site
et
immedi
vicin
inflamoqantitrypsin
arginin
tabl
antitrypsin
realiz
oximatori
focu
oxygen
free
effect
inhibitor
convert
dation
inactiv
txantitrypsin
radic
releas
leucocyt
infrom
metserpin
argserpin
ie
also
led
understand
activ
oqantitrypsin
oxid
lost
abil
inhibit
elastas
number
lung
patholog
particureact
centr
methionin
oxygen
becam
highli
effect
inhibitor
lar
emphysema
heavi
freerad
short
radiu
thrombin
fig
cigarett
smoker
activ
beyond
area
identif
aantitrypsin
reactiv
centr
methionin
unoxid
cqantitrypsin
readili
neupittsburgh
rais
possibl
antitrypsin
fit
activesit
pocket
traliz
elastas
way
engin
mutat
reactiv
elastas
therefor
function
vulner
methionin
becom
centr
natur
mutat
bait
entrap
howev
advantag
allow
defin
pittsburgh
variant
produc
methionin
readili
oxidiz
zone
elastas
activ
potent
anticoagul
obviou
methionin
suiphoxid
howev
evolut
obvious
therapeut
applic
potenti
consider
larger
bulk
time
adjust
introduct
recent
achiev
courtney
readili
fit
elastas
pocket
cigarett
smoke
abil
colleagu
use
sitespecif
consequ
oxid
ctantitrypsin
oxid
switch
inhibitori
mutagenesi
give
high
yield
ineffect
inhibitor
neutrophil
activ
cxlantitrypsin
becom
arginin
mutant
e
coli
vari
elastas
provid
real
problem
grossli
disadvantag
replac
amino
acid
sever
situat
oxismok
accumul
leucoequ
possibl
engin
specif
dativ
stress
occur
particularli
cyte
lung
henc
combin
inhibitor
serin
proteinas
expos
area
lung
suffici
exposur
elastas
releas
oxiof
complement
inflammatori
give
demonstr
inactiv
et
dativ
inactiv
eqantitrypsin
cascad
antitrypsin
occur
direct
one
immedi
question
exposur
oxid
ozon
poiluth
pittsburgh
variant
sitedirect
whether
would
possibl
produc
tion
therapeut
use
pure
mutat
oxidationresist
cqantitrypsin
oxygen
also
occur
theme
review
intraven
replac
therapi
excess
accumul
leucocyt
specif
serpin
primarili
plasma
concentr
txantitrypsin
lung
heavi
smoker
depend
singl
amino
acid
alreadi
test
patient
evolut
provid
reactiv
centr
possibl
genet
defici
meet
worldvulner
reactiv
centr
alanti
specif
inhibit
could
wide
need
therapi
requir
trypsin
answer
seem
thai
chang
alter
reactiv
centr
microbi
product
ctantitrypsin
abil
switch
arantitrypsin
amino
acid
becam
realiti
use
recombin
dna
techniqu
provid
mean
essenti
identif
extraordinari
get
microb
produc
tissu
breakdown
occur
natur
mutat
found
improv
cqantitrypsin
immedi
vicin
inflammatori
male
pittsburgh
obviou
way
focu
perhap
area
regrowth
sever
bleed
disord
caus
replac
reactiv
centr
methionin
exampl
consid
tissu
regreatli
increas
antithrombin
activ
valin
good
yield
action
thorn
thumb
presenc
electrophoret
valinecqantitrypsin
valserpin
thorn
rapidli
surround
leucoabnorm
atantitrypsin
suggest
achiev
yeast
hallewel
cyte
must
kill
associ
diseas
caus
activesit
colleagu
e
coli
